Anita H. Clayton, MD

Two decades after a landmark STAR*D trial recalibrated expectations, Dr. DeBattista argues the standard of care has barely moved, and that measurement-based care remains the underused lever.

The side effect that stops the drug is usually the one nobody warned about. The panel works through what belongs in the first conversation and how often to reassess for suicidality.

Start low and go slow collides with therapeutic urgency more often than guidelines admit. Dr. DeBattista walks through the hepatic, renal, and cytochrome considerations that force a prescriber's hand.

The weeks spent waiting for an antidepressant to work are a window for dropout and risk. The panel debates who earns a faster-acting option up front and what monitoring that choice requires.

A significant improvement on a rating scale can still leave a patient unable to function. Dr. DeBattista explains how he defines meaningful improvement and when non-response should change the plan.

One approval took decades and a stack of complete response letters. Dr. Clayton reviews where these two agents fit, what their trials showed, and why patient preference should drive the choice.

Anita Clayton, MD, explains why sexual dysfunction affects most patients with major depression and how it overlaps with anhedonia.

An oral glutamatergic option without the logistics of ketamine. Dr. Shirikjian walks through the trial program, the week-one separation, and the mechanism she had to unlearn to understand.

Older antidepressants did not get less effective, only less convenient. Dr. Clayton explains where tricyclics and MAOIs still belong, and when combining psychotherapy with medication outperforms either alone.

Anita Clayton, MD, explains how anhedonia points to past trauma and to future suicide and relapse risk, and how clinicians can screen for it quickly.

Most depression in this country is never treated by a psychiatrist. The panel maps which parts of the journey primary care can own, where handoffs break down, and what safety demands first.

The imaging evidence is associational, not causal. The panel weighs whether that is reason enough for a skeptical colleague to treat depression earlier, and how anxiety complicates the picture.

Learn why SSRIs impair sex and how bupropion, PDE5 inhibitors, buspirone, and newer agents can prevent or reverse antidepressant sexual side effects.

Experts unpack screening for sexual dysfunction in psychiatric care, menopause and meds impacts, and when flibanserin may help restore desire.

Learn how to spot and treat sexual dysfunction in psychiatric care—screen causes, manage SSRI effects, and choose libido-friendly medications.

Clinicians learn how to assess and treat sexual dysfunction in depression, menopause, and psych meds—plus drug options that preserve desire and arousal.

Fatigue and poor sleep send patients to primary care, but a CBC and a thyroid panel will not find depression. The panel examines what actually separates major depression from its mimics.

Depression rarely arrives named. The panel opens on the presentations that mask it, the risk factors worth flagging in primary care, and the lag between first symptom and adequate treatment.

A panel of expert psychiatrists define deprescribing as ongoing medication review, guiding safer, personalized psychopharmacology amid polypharmacy, misdiagnosis, and fragmented care.

ASCP panel offers deprescribing guidance to curb psychiatric overprescribing, simplify polypharmacy, and improve outcomes with tapering and

Expert psychiatrists share new ASCP deprescribing guidance, tackling overprescribing, primary-care challenges, and practical tapering strategies to improve safer, patient-centered mental health care.

Explore practical ways psychiatrists address sexual side effects and adjust medication for older adults.

Learn more about strategies for deprescribing, and the importance of finding the most effective medication possible.

Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.

Anita H. Clayton, MD, welcomes us all to the 2024 ASCP Annual Meeting!

Postpartum depression and major depressive disorder in pregnant and postpartum women are severely underdiagnosed and undertreated. How can we more effectively help this patient population?

Sex and gender, influenced by genetics, epigenetics, and environmental/social stressors, must be considerations in evaluating every patient.

What are the implications of maternal mental health not only for mothers, but also for children, families, and society as a whole?

Flibanserin is a breakthrough. We will finally be able to talk to women with hypoactive sexual desire disorder about a treatment that has FDA approval.